[{"orgOrder":0,"company":"Hainan Poly Pharm","sponsor":"Imunon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"DNA-based COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hainan Poly Pharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Hainan Poly Pharm \/ Celsion","highestDevelopmentStatusID":"4","companyTruncated":"Hainan Poly Pharm \/ Celsion"}]

Find Clinical Drug Pipeline Developments & Deals by Hainan Poly Pharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of agreement, Poly Pharm will manufacture clinical batches and, if approved, will also manufacture commercial batches for Celsion’s vaccine based on TheraPlas technology. TheraPlas underlies Celsion’s GEN-1 product and its PLACCINE va...

                          Brand Name : Placcine Covid 19 Vaccine

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 17, 2021

                          Lead Product(s) : DNA-based COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Imunon

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank